12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zevalin ibritumomab tiuxetan: Phase II started

Spectrum began an open-label, North American Phase II trial to evaluate IV Zevalin plus rituximab with or without motexafin gadolinium, a radiation and chemotherapy sensitizing agent, in about 100 patients.

Zevalin is approved in the U.S. to treat previously untreated follicular NHL in patients who achieve a partial or complete response to...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >